CGRP Education & Research Forum
Already a member? Become a member Register
IHC 2019

Join us now

The Calcitonin Gene-Related Peptide (CGRP) Forum has been established by an international group of clinicians and researchers. It provides all healthcare professionals with open and free access to independent news, information, comment and resources about the exciting potential of CGRP as a novel therapeutic target for the prevention of migraine in millions of people worldwide.

View invitations from the editors
Become a member of CGRP Forum now


Extensive clinical trial data support the efficacy and safety of anti-CGRP therapies in patients with migraine but there is still much to be learned about their precise role in daily practice. In the first of a series of videos about what comes next for anti-CGRP therapy, Peter Goadsby discusses the challenges that still need to be addressed and looks forward to important advances that will enable clinicians to serve patients better.

Why is CGRP an important therapeutic target?

Multiple lines of evidence support a role for CGRP in migraine pathophysiology.

Its blockade is now a potentially important therapeutic target for migraine prevention.

Read more Become a member

Is anti-CGRP therapy approved for your patients?

Take a look at our new expert guide to the regulatory status and approved indications for anti-CGRP therapies worldwide.

Read More
From the Editors
Our distinguished Editors discuss the latest developments and provide their views:Will CGRP antibodies put an end to migraine?View all articles
Members get free, open access - Register now »
Easy-to-access digests of all the key trials completed & ongoing:Eptinezumab (ALD403)Erenumab (AMG 334)Galcanezumab (LY2951742)Fremanezumab (TEV-48125)View all Trials